Mangia, A., Francavilla, R., Merola, V., Barbaríni, G., Russello, M., Nosotti, L., et al. (2012). Benefit of weight bosed dosoges of Ribavirin (RBV) in combinotion with Peg-lnterferon (PeglFN) a2a in naive patients with HCV2 and HCV3: results of an ltalian Randomized Controlled Triol, the WRITE study. HEPATOLOGY, 56(n° 4 (suppl)), 1001 A-1001 A.

Benefit of weight bosed dosoges of Ribavirin (RBV) in combinotion with Peg-lnterferon (PeglFN) a2a in naive patients with HCV2 and HCV3: results of an ltalian Randomized Controlled Triol, the WRITE study

MONTALTO, Giuseppe;
2012-01-01

2012
American Association for the Study of Liver Disease
Boston
ottobre 2012
63rd
Mangia, A., Francavilla, R., Merola, V., Barbaríni, G., Russello, M., Nosotti, L., et al. (2012). Benefit of weight bosed dosoges of Ribavirin (RBV) in combinotion with Peg-lnterferon (PeglFN) a2a in naive patients with HCV2 and HCV3: results of an ltalian Randomized Controlled Triol, the WRITE study. HEPATOLOGY, 56(n° 4 (suppl)), 1001 A-1001 A.
File in questo prodotto:
File Dimensione Formato  
AASLD.pdf

Solo gestori archvio

Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/75024
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact